Jeil Pharmaceutical and Jeil Pharma Holdings Reappoint Sung Seokje and Han Sangcheol as Inside Directors at Shareholders' Meetings (Comprehensive)

Jeil Pharmaceutical and Jeil Pharma Holdings held their respective annual general meetings at their headquarters in Seocho-gu, Seoul on the 24th.

At the 9th annual general meeting, Jeil Pharmaceutical reported its key management achievements for the previous year, posting consolidated sales of 567.2 billion won, operating profit of 20.7 billion won, and net profit of 32.0 billion won. These results reflect a significant improvement in profitability, driven by an expanded product-centered sales structure and improved cost of sales ratio.

Jeil Pharmaceutical and Jeil Pharma Holdings held their respective annual general meetings at their headquarters in Seocho-gu, Seoul on the 24th. Jeil Pharmaceutical

At the shareholders' meeting, the following agenda items were approved as originally proposed: approval of financial statements and consolidated financial statements, amendments to the articles of incorporation, appointment of directors, appointment of outside directors, appointment of outside directors as audit committee members, separate election of outside directors as audit committee members, revision of the executive retirement pay regulations, and approval of the ceiling on directors' remuneration.

Under the director appointment agenda, Directors Sung Seokje and Han Sangcheol were reappointed. Additionally, Kim Sunghoon was newly appointed as an outside director and also as an audit committee member. Furthermore, Kim Wangseong was reappointed as an outside director serving as an audit committee member.

Sung Seokje, CEO of Jeil Pharmaceutical, stated, "Jeil Pharmaceutical has transitioned from a product-distribution-focused structure to a business portfolio centered on its own products, laying the foundation for qualitative growth. Going forward, we will seek to expand prescriptions and strengthen product competitiveness centered on our proprietary drug, Jakubo, while also reinforcing our mid- to long-term growth base through R&D pipelines such as JP-2266, a next-generation dual-mechanism type 2 diabetes treatment."

Jeil Pharma Holdings also held its 66th annual general meeting, where it reported major management results for the previous year. Jeil Pharma Holdings posted consolidated sales of 657.6 billion won, operating profit of 38.7 billion won, and net profit of 34.6 billion won last year. The improved profitability of its key subsidiary, Jeil Pharmaceutical, and increased efficiency in its business structure drove the recovery in results.

At the shareholders' meeting, the following items were approved as originally proposed: approval of financial statements and consolidated financial statements, amendments to the articles of incorporation, appointment of directors, appointment of outside directors, appointment of outside directors as audit committee members, revision of the executive retirement pay regulations, and approval of the ceiling on directors' remuneration.

Under the director appointment agenda, Directors Moon Bonghee and Lee Juhyun were reappointed, and Min Kyungryul was newly appointed as a director. Additionally, Jeon Seungbae was reappointed as an outside director and audit committee member.

In addition, a cash dividend of 70 won per common share was also approved.

Han Sangcheol, CEO of Jeil Pharma Holdings, stated in his greeting, "Last year, despite an uncertain business environment, Jeil Pharma Holdings achieved a turnaround to profitability by advancing our business structure and strengthening our internal capabilities. This year, we will continue to pursue the sustainable growth of our business subsidiaries and enhancement of shareholder value through thorough risk management and efficient management support activities."

Through this shareholders' meeting, Jeil Pharmaceutical and Jeil Pharma Holdings have clarified the grounds for funding and the acquisition/disposal of treasury shares, incorporated recent amendments to the Commercial Act, and enhanced the flexibility of capital policy and operations, as well as strengthened the foundation for shareholder-friendly policies through amendments to the articles of incorporation, including improvements to dividend procedures.

This content was produced with the assistance of AI translation services.